March 10, 2016
PharmAlliance, the research, education and practice partnership between three of the world’s most highly regarded schools of pharmacy — Monash University, University College London and the University of North Carolina at Chapel Hill — has announced its first round of grant funding.
Established in March 2015, PharmAlliance enables the partners to pursue new educational, practice and research collaborations to address major international issues in the fields of drug discovery and development, nanomedicine and nanotechnology development and clinical pharmacology.
“Many of the problems we’re facing are too big for one institution on its own to solve. We strongly believe that combining our intellectual resources is the best way to tackle them,” said Bill Charman, Ph.D., dean of the Faculty of Pharmacy and Pharmaceutical Sciences at Monash University. “The fact that we have all contributed substantial resources to PharmAlliance is testament to how seriously we take it.”
“PharmAlliance brings together the very top researchers in their fields in the world, allowing us to catalyse existing areas of excellence into internationally leading collaborations,” said Professor Duncan Craig, Ph.D., director of the UCL School of Pharmacy.
Two Pharmacy Education Projects Funded
The first round includes funding for two projects aimed at further improving the quality of pharmacy education.
One project, led by UCL’s Felicity Smith, Ph.D., will develop an education module to prepare pharmacy students to provide better health care to adolescents, an area that has been highlighted by the World Health Organization as needing improvement.
The second education project, led by UNC’s Alex Tropsha, Ph.D., aims to use emerging developments in information technology to create a virtual reality environment that enables students to explore biological processes, including the way the body reacts to drugs.
Four Research Projects Funded
- A project led by UCL’s Richard Angell, Ph.D., aims to develop small-molecule inhibitors that will act as an antiviral across all four dengue virus serotypes. Dengue can cause haemorrhagic fever or death, and there are currently no antivirals to control it. The recently launched DengVaxia provides protection in 66 percent of patients aged 9 to 16 and significantly lower protection vs dengue types 1 and 2 compared to 3 and 4.
- Research led by Monash’s Joe Nicolazzo, Ph.D., aims to fill a knowledge gap and generate basic information regarding drug disposition in Alzheimer’s disease. Reports suggest that Alzheimer’s patients tolerate medicines differently from healthy volunteers. This, coupled with a decreased ability to competently report their own symptoms, means they risk misdiagnosis. Precision medicine could succeed in improving their quality of life.
- Research led by UNC’s Lindsey James, Ph.D., will explore the implications of the discovery of small molecule inhibitors that may help prevent the devastating effects of breast cancer mutations.
- A team led by Monash’s Sue Charman, Ph.D., will conduct in vitro and in vivo evaluation of leads in support of the development of a treatment for portal hypertension, which is an abnormally high blood pressure in a major vein that brings blood form the intestine to the liver.
“Although this is just the beginning of our partnership, I think you can already appreciate from the projects we’ve chosen to support just how ambitious it is,” said Bob Blouin, Pharm.D., dean of the UNC Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. “We believe that our PharmAlliance partnership has the potential to improve treatments and impact patients’ lives by bringing together some of the world’s best academic pharmaceutical researchers.”